Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review

References

• Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017;10(1):94.
   PubMed Web of Science ®Google Scholar
• Harrison AM, Thalji NM, Greenberg AJ, et al. Rituximab for non-Hodgkin’s lymphoma: a story of rapid success in translation. J Clin Transl Sci. 2014;7(1):82–86.
   Google Scholar
• Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055–2063.
   PubMed Web of Science ®Google Scholar
• Bachireddy P, Burkhardt UE, Rajasagi M, et al. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015;15(4):201–215.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873–1883.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–1093.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 Apr 1;32(10):1020.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. NEJM. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. NEJM. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Shih YC, Smieliauskas F, Geynisman DM, et al. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33(19):2190.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Atkins MB, Dicker AP, et al. the value of cancer immunotherapy summit at the 2016 society for immunotherapy of cancer 31 st anniversary annual meeting. Am J Clin Dermatol. 2017;18(1):1–10.
   PubMedGoogle Scholar
• Saret CJ, Winn AN, Shah G, et al. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015;125(12):1866–1869.
   PubMed Web of Science ®Google Scholar
• Prasad V, Sham M. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015;126(15):1860–1861.
   PubMed Web of Science ®Google Scholar
• Truong J, Cheung MC, Mai H, et al. The impact of cancer drug wastage on economic evaluations. Cancer. 2017;123(18):3583–3590.
   PubMed Web of Science ®Google Scholar
• Lien K, Cheung MC, Chan KK. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract. 2016;12(4):369–379.
   PubMed Web of Science ®Google Scholar
• Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21(2):165–171.
   PubMed Web of Science ®Google Scholar
• Khor S, Beca J, Krahn M, et al. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014;14(1):586.
   PubMedGoogle Scholar
• Howard DR, Munir T, McParland L, et al. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy in Chronic lymphocytic leukaemia (ARCTIC) trial. Health Technol Assess. 2017;21(28):1–374.
   Web of Science ®Google Scholar
• Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma. 2008;49(2):227–236.
   PubMed Web of Science ®Google Scholar
• Blommestein HM, Issa DE, Pompen M, et al. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. Eur J Haematol. 2014;92(5):398–406.
   PubMed Web of Science ®Google Scholar
• Chen Q, Ayer T, Nastoupil LJ, et al. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health. 2015;18(2):189–197.
   PubMed Web of Science ®Google Scholar
• Deconinck E, Miadi-Fargier H, Pen CL, et al. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoecon. 2010;28(1):35–46.
   PubMed Web of Science ®Google Scholar
• Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65–70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma. 2008;8(3):166–170.
   PubMedGoogle Scholar
• Hornberger J, Chien R, Friedmann M, et al. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma. 2012;53(12):2371–2377.
   PubMed Web of Science ®Google Scholar
• Kasteng F, Erlanson M, Hagberg H, et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 2008;47(6):1029–1036.
   PubMed Web of Science ®Google Scholar
• Prettyjohns M, Hoskin P, McNamara C, et al. The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. Br J Haematol. 2018;180(1):52–59.
   PubMed Web of Science ®Google Scholar
• Prica A, Chan K, Cheung M. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis. Cancer. 2015;121(15):2637–2645.
   PubMed Web of Science ®Google Scholar
• Adena M, Houltram J, Mulligan SP, et al. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoecon. 2014;32(2):193–207.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(2):225–234.
   PubMed Web of Science ®Google Scholar
• Mandrik O, Corro Ramos I, Knies S, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Manag Res. 2015;7:279–289.
   PubMed Web of Science ®Google Scholar
• Müller D, Fischer K, Kaiser P, et al. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(5):1130–1139.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig. 2008;28(1):55–65.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Marra CA, Connors JM, et al. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010;13(6):703–711.
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Gleeson ML, Mikhael J, et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012;118(24):6079–6088.
   PubMed Web of Science ®Google Scholar
• Ray JA, Carr E, Lewis G, et al. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin’s lymphoma in the UK. Value Health. 2010;13(4):346–357.
   PubMed Web of Science ®Google Scholar
• Nam J, Milenkovski R, Yunger S, et al. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. J Med Econ. 2018;21(1):47–59.
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Griffiths RI, Gleeson ML, et al. Impact on medical cost, cumulative survival, and cost-effectiveness of adding Rituximab to first-line Chemotherapy for Follicular Lymphoma in elderly patients: an observational Cohort study based on SEER-medicare. J Cancer Epidemiol. 2012;2012(2012):1–13.
   Google Scholar
• Sabater E, López-Guillermo A, Rueda A, et al. Cost-effectiveness analysis of Bendamustine Plus Rituximab as a first-line treatment for patients with Follicular Lymphoma in Spain. Appl Health Econ Health Policy. 2016;14(4):465–477.
   PubMed Web of Science ®Google Scholar
• Dewilde S, Woods B, Castaigne JG, et al. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales. J Med Econ. 2014;17(2):111–124.
   PubMedGoogle Scholar
• Van KM, Gairy K, Seshagiri D, et al. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC Cancer. 2016;16(1):598.
   PubMedGoogle Scholar
• Casado LF, Hernández JÁ, Jarque I, et al. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia. Eur J Haematol. 2018;100(3):264–272.
   PubMed Web of Science ®Google Scholar
• Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700–1709.
   PubMed Web of Science ®Google Scholar
• Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–1197.
   PubMed Web of Science ®Google Scholar
• Soini EJ, Martikainen JA, Vihervaara V, et al. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma. Clin Ther. 2012;34(4):915–925.
   PubMed Web of Science ®Google Scholar
• Kongnakorn T, Sterchele JA, Salvador CG, et al. Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. Clinicoecon Outcomes Res. 2014;6:141–149.
   PubMedGoogle Scholar
• Lu L, Peters J, Roome C, et al. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia. Int J Technol Assess Health Care. 2012;28(3):241–248.
   PubMed Web of Science ®Google Scholar
• Babashov V, Begen MA, Mangel J, et al. Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma. Curr Oncol. 2017;24(1):6–14.
   PubMed Web of Science ®Google Scholar
• Hui L, Von KG, Wang R, et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017;123(19):3763–3771.
   PubMed Web of Science ®Google Scholar
• Huntington SF, Von KG, Davidoff AJ, et al. Cost-effectiveness analysis of Brentuximab Vedotin with Chemotherapy in newly diagnosed Stage III and IV Hodgkin Lymphoma. J Clin Oncol. 2018;36(33):3307.
   Web of Science ®Google Scholar
• Parker C, Woods B, Eaton J, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. J Med Econ. 2017;20(1):8–18.
   PubMed Web of Science ®Google Scholar
• Sinha R, Redekop WK. Cost-effectiveness of Ibrutinib compared with Obinutuzumab with Chlorambucil in untreated Chronic Lymphocytic Leukemia patients with Comorbidities in the United Kingdom. Clin Lymphoma Myeloma Leuk. 2018;18(2):131–142.
   PubMed Web of Science ®Google Scholar
• Guzauskas GF, Masaquel A, Reyes C, et al. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. J Med Econ. 2018;21(10):960–967.
   PubMed Web of Science ®Google Scholar
• Haukaas FS, Ohna A, Krivasi T. Cost-effectiveness of Obinutuzumab in combination with Bendamustine followed by Obinutuzumab maintenance versus Bendamustine alone in treatment of patients with Rituximab-Refractory Follicular Lymphoma in Norway. Appl Health Econ Health Policy. 2018;16(4):569–577.
   PubMed Web of Science ®Google Scholar
• Hatswell AJ, Thompson GJ, Maroudas PA, et al. Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia. Cost Eff Resour Alloc. 2017;15(1):8.
   PubMedGoogle Scholar
• Herring W, Pearson I, Purser M, et al. Cost effectiveness of Ofatumumab plus Chlorambucil in first-line Chronic Lymphocytic Leukaemia in Canada. Pharmacoeconomics. 2016;34(1):77–90.
   PubMed Web of Science ®Google Scholar
• Pelligra CG, Parikh K, Guo S, et al. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple Myeloma in the United States. Clin Ther. 2017;39(10):1986–2005.
   PubMed Web of Science ®Google Scholar
• Delea TE, Amdahl J, Boyko D, et al. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ. 2017;20(9):911–922.
   PubMed Web of Science ®Google Scholar
• Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of Chimeric Antigen Receptor T-Cell Therapy for pediatric patients with relapsed or refractory Leukemia. JAMA Pediatr. 2018;172(12):1161–1168.
   PubMed Web of Science ®Google Scholar
• Soini E, Hautala A, Poikonen E, et al. Cost-effectiveness of first-line Chronic Lymphocytic Leukemia treatments when full-dose Fludarabine is unsuitable. Clin Ther. 2016;38(4):889–904.
   PubMed Web of Science ®Google Scholar
• Mittmann N, Isogai PK, Connors MJ, et al. Economic analysis of alemtuzumab (MabCampath®) in fludarabinerefractory chronic lymphocytic leukemia. Open PharmacoEcon Health Econ J. 2012;4(1):18–25.
   Google Scholar
• Scott WG, Scott HM. Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia. Clin Drug Investig. 2007;27(11):755–764.
   PubMed Web of Science ®Google Scholar
• Large S, Hettle R, Balakumaran A, et al. Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective. J Med Econ. 2018;1–10. DOI:https://doi.org/10.1080/13696998.2018.1534738.
   Google Scholar
• Becker U, Briggs AH, Moreno SG, et al. Cost-effectiveness model for Chemoimmunotherapy options in patients with previously untreated Chronic Lymphocytic Leukemia unsuitable for full-dose fludarabine-based therapy. Value Health. 2016;19(4):374–382.
   PubMed Web of Science ®Google Scholar
• Blommestein HM, De Groot S, Aarts MJ, et al. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leuk Res. 2016;50:37–45.
   PubMed Web of Science ®Google Scholar
• Paquete AT, Miguel LS, Becker U, et al. Cost-effectiveness analysis of Obinutuzumab for previously untreated Chronic Lymphocytic Leukaemia in Portuguese patients who are unsuitable for full-dose Fludarabine-Based Therapy. Appl Health Econ Health Policy. 2017;15(4):501–512.
   PubMed Web of Science ®Google Scholar
• Casado LF, Burgos A, González-Haba E, et al. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. Clinicoecon Outcomes Res. 2016;8:475–484.
   PubMed Web of Science ®Google Scholar
• Batty N, Shatzel J, Wiles S, et al. Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies. J Cancer Policy. 2014;2(2):40–44.
   Google Scholar
• Zafar SY, McNeil RB, Thomas CM, et al. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11(2):145–150.
   PubMed Web of Science ®Google Scholar
• Lathan CS, Cronin A, Tucker-Seeley R, et al. Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol. 2016;34(15):1732–1740.
   PubMed Web of Science ®Google Scholar
• Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534–2542.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980–986.
   PubMed Web of Science ®Google Scholar
• Imbens G, Wooldridge J. Recent developments in the econometrics of program evaluation. J Econ Lit. 2009;3(1):5–86.
   Google Scholar